The emergency phase of the COVID-19 pandemic is over but the story of BioNTech, which emerged as one of the leading vaccine makers during the crisis, is still ongoing.

To that end, National Geographic announced Wednesday morning that it is following Uğur Şahin and Özlem Türeci, the husband-and-wife co-founders of the German biotech, as part of a documentary with the working title The Cancer Vaccine.

As the name suggests, the film will follow BioNTech’s efforts to parlay the technology used for the COVID-19 vaccine developed in conjunction with Pfizer in an effort to develop a class of medicines that will cure cancer. 

The project will be produced by Oxford Films and directed by BAFTA-winning filmmaker Patrick Forbes.

“The Cancer Vaccine will give viewers a front-row seat to one of the biggest events in history unfolding in real time – the scientists racing to find a potential cure for cancer,” said Tom McDonald, EVP of global factual and unscripted content at National Geographic, in a statement. “With unprecedented inside access, we are honored to be able to shine a light on the heroes – the scientists, patients and people, who are working to combat this disease that affects far too many of our friends, families and neighbors.”

National Geographic stated that its documentary will “be there every step of the way” as BioNTech seeks to follow up its life-saving COVID vaccines with a cure for cancer, one of the most elusive vaccines in the history of medicine.

BioNTech’s experimental cancer vaccine candidate has shown potential for treating pancreatic cancer, according to data from a small study that was released last month.

While BioNTech made the most of its opportunity with the COVID vaccine, there has been a dropoff in demand and sales of the jab as the world has returned to something close to normal following the three-year pandemic.

In its Q1 earnings report, BioNTech said decreasing sales of its COVID vaccine contributed to its cost of sales falling from €1.3 billion to €96 million.

The film announcement comes after months of BioNTech gradually pivoting to options in the future that exist outside of the COVID space.

In April, BioNTech signed a partnership agreement with DualityBio for access to antibody-drug conjugate (ADC) therapeutics candidates targeting cancer and autoimmune diseases. The deal includes a $170 million upfront payment and milestone payments that could add up to $1.5 billion.

In January, the company bought InstaDeep for about $440 million in initial cash as part of an effort to bolster its cancer immunotherapy and vaccine pipelines.